Saturday 17 October 2026
Export LEXX’s income statement to Excel — free account
Lexaria Bioscience Corp.
LEXX Healthcare Biotechnology
Lexaria Bioscience Corp.’s revenue for fiscal 2025 (year ended August 2025) was $705,900.00, up 52.0% from fiscal 2024. In the quarter to May 2026, revenue fell 89.1%, EPS grew 61.9% and free cash flow grew 53.9%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
2.92
0.07
−2.34%
Follow LEXX
| Aug '16 | Aug '17 | Aug '18 | Aug '19 | Aug '20 | Aug '21 | Aug '22 | Aug '23 | Aug '24 | Aug '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | 3 | 5 | 2 | 4 | 5 | 4 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 22.37 | 15.18 | 6.10 | 37.81 | 68.21 | 30.73 | 97.40 | 22.60 |
Altman Z-Score |
(34.71) | — | 115.15 | (3.57) | (14.44) | 77.04 | 43.21 | (16.64) | 14.74 | (23.89) |
Altman Z″-Score (non-manufacturers) |
(93.43) | — | 20.49 | (18.09) | (30.43) | 62.85 | 23.52 | (51.64) | (11.63) | (63.83) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | — | (4.36) | (5.02) | (1.89) | (4.17) | (4.12) | (2.69) | (3.56) |
P/Operating CF |
(3.27) | (2.34) | (11.58) | (4.59) | (3.00) | (24.57) | (14.81) | (4.29) | (23.91) | (6.04) |
P/B ratio |
0.00 | 0.51 | 4.06 | 1.36 | 0.77 | 2.09 | 2.28 | 2.59 | 5.90 | 6.13 |
Price to Tangible BV |
0.00 | 0.52 | 4.32 | 1.52 | 0.88 | 2.15 | 2.44 | 3.13 | 6.33 | 6.95 |
EV/Sales |
0.00 | 0.00 | 18.36 | 9.12 | 2.14 | 21.60 | 44.38 | 24.48 | 83.42 | 19.90 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | (3.16) | (0.67) | (0.26) | (3.91) | (2.32) | (0.94) | (7.81) | (1.34) |
EV/FCF |
0.00 | 0.00 | (3.06) | (0.54) | (0.20) | (4.10) | (2.24) | (0.91) | (7.50) | (1.33) |
Quick Ratio |
0.52 | 27.94 | 45.94 | 8.79 | 7.20 | 78.89 | 32.80 | 5.99 | 6.10 | 1.56 |
Current Ratio |
1.18 | 30.29 | 52.39 | 9.86 | 8.53 | 81.17 | 35.97 | 8.04 | 7.18 | 2.32 |
Net Debt/EBITDA |
(0.22) | 1.30 | 0.29 | 0.48 | 0.31 | 2.12 | 0.95 | 0.23 | 1.15 | 0.17 |
Debt/Assets |
66.43% | 0.00% | 0.32% | 0.00% | 2.36% | 0.06% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
1.42 | 0.01 | 0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.02 | 0.22 | 0.29 | 0.09 | 0.11 | 0.09 | 0.02 | 0.04 | 0.08 | 0.11 |
Operating CF/Net income |
0.54 | 0.70 | 0.38 | 0.72 | 0.67 | 0.99 | 0.67 | 0.88 | 0.86 | 0.88 |
Capex/Depreciation |
0.00 | 0.00 | (37.13) | (12.69) | (0.23) | 1.31 | (1.76) | (1.17) | (2.48) | (1.14) |
Interest Coverage |
(143.14) | 0.00 | — | — | — | — | — | — | — | — |
| (74.25%) | (114.25%) | (245.03%) | (170.46%) | (158.21%) | (51.81%) | (70.25%) | (129.26%) | (112.10%) | (231.96%) | |
| (70.90%) | (659.83%) | (440.85%) | (162.85%) | (142.97%) | (50.04%) | (68.90%) | (122.09%) | (96.98%) | (182.50%) | |
ROIC |
0.00% | 0.00% | (568.66%) | (156.74%) | (209.81%) | (269.29%) | (281.06%) | (339.63%) | (325.87%) | (1,168.81%) |
Return on Tangible Assets |
(1,541.62%) | (69.10%) | (294.83%) | (186.84%) | (180.17%) | (31.81%) | (102.40%) | (311.79%) | (82.16%) | (540.28%) |
Average Days of Receivables |
1,175.71 | 259.98 | 223.90 | 447.81 | 363.96 | 172.93 | 288.40 | 204.45 | 121.46 | 190.49 |
Research and Development Expense of Revenue |
22.11% | 85.22% | 113.75% | 249.64% | 122.97% | 174.75% | 721.50% | 1,621.00% | 508.42% | 1,167.13% |
Selling, General and Administrative Expense of Revenue |
2,941.28% | 2,882.23% | 112.88% | 381.22% | 1,263.37% | 687.88% | 1,942.01% | 1,353.67% | 829.64% | 615.55% |
Intangible Assets out of Total Assets |
0.10 | 0.00 | 0.06 | 0.10 | 0.10 | 0.03 | 0.06 | 0.15 | 0.06 | 0.07 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 780.82% | 386.88% | 393.68% | 68.49% | 764.53% | 75.33% | 106.01% | 121.76% |
Graham Net Nets |
0.00 | 1.91 | 0.23 | 0.48 | 0.82 | 0.45 | 0.39 | 0.25 | 0.15 | 0.12 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(46.07%) | (46.07%) | (68.19%) | (123.10%) | (220.66%) | (15.44%) | (42.21%) | (96.14%) | (12.87%) | (73.33%) |
Free Cash Flow Yield |
0.00% | 0.00% | (26.86%) | (111.74%) | (171.78%) | (13.92%) | (29.03%) | (87.08%) | (11.41%) | (66.13%) |
Revenue per Share |
0.02 | 0.03 | 2.75 | 1.29 | 1.70 | 2.47 | 0.65 | 0.51 | 0.56 | 0.59 |
Operating CF per Share |
(0.40) | (0.67) | (15.98) | (17.39) | (14.16) | (13.62) | (12.43) | (13.33) | (6.00) | (8.70) |
Capex per Share |
0.00 | 0.00 | (0.54) | (4.45) | (0.18) | 0.66 | (0.46) | (0.38) | (0.23) | (0.08) |
Free Cash Flow per Share |
(0.40) | (0.67) | (16.52) | (21.84) | (14.34) | (12.96) | (12.89) | (13.71) | (6.23) | (8.79) |
Cash per Share |
0.06 | 1.29 | 11.02 | 7.81 | 7.10 | 40.12 | 15.70 | 3.35 | 7.94 | 1.64 |
Shareholders Equity per Share |
0.16 | 1.53 | 15.15 | 14.41 | 13.42 | 44.60 | 19.45 | 6.07 | 9.27 | 2.17 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.16 | 1.53 | 15.15 | 14.41 | 13.42 | 44.60 | 19.45 | 6.07 | 9.27 | 2.17 |
Free Cash Flow |
(0.66) | (1.31) | (2.60) | (3.77) | (2.65) | (3.80) | (5.06) | (6.05) | (5.15) | (10.55) |
Working Capital |
0.08 | 2.70 | 2.24 | 1.63 | 1.70 | 12.29 | 6.78 | 1.88 | 6.80 | 1.97 |
Capital Expenditures |
(0.02) | (0.01) | (0.09) | (0.77) | (0.03) | 0.19 | (0.18) | (0.17) | (0.19) | (0.10) |
Net Current Asset Value |
0.03 | 2.70 | 2.24 | 1.63 | 1.58 | 12.24 | 6.78 | 1.75 | 6.69 | 1.90 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.20 | 3.46 | 0.11 | (0.27) | 0.71 | 0.75 | 0.41 | 0.14 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.24 | 0.79 | 1.92 | 0.10 | 0.30 | 0.40 | 0.33 | 0.57 | 0.30 | 0.38 |
Cash ROIC |
(89.82%) | (23.42%) | (62.98%) | (98.30%) | (68.68%) | (15.29%) | (36.68%) | (145.53%) | (36.21%) | (230.84%) |
Accounts Receivable Turnover |
0.46 | 0.72 | 2.79 | 0.83 | 1.07 | 2.20 | 0.94 | 1.38 | 3.30 | 2.70 |
Accounts Payable Turnover |
0.75 | 0.51 | 0.74 | 0.27 | 0.89 | 1.82 | 0.56 | 0.16 | 0.01 | 0.00 |
Inventory Turnover |
0.46 | 0.31 | 0.33 | 0.21 | 0.81 | 2.39 | 2.11 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
711.04 | 381.38 | 518.53 | 2,174.06 | 319.10 | 219.67 | 769.65 | 2,779.79 | 81,090.83 | 197,775.93 |
Days of Inventory on Hand |
1,064.19 | 786.15 | 1,263.02 | 2,030.61 | 429.26 | 61.63 | 195.21 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.09 | 0.09 | 0.16 | 0.27 | 0.29 | 0.33 | 0.27 | 0.16 | 0.14 | 0.26 |
Average Payables |
0.06 | 0.06 | 0.03 | 0.09 | 0.11 | 0.10 | 0.13 | 0.20 | 0.65 | 1.26 |
Average Inventory |
0.10 | 0.10 | 0.08 | 0.11 | 0.12 | 0.07 | 0.03 | — | — | — |
Average Assets |
1.71 | 0.28 | 1.50 | 2.55 | 2.75 | 8.05 | 10.55 | 5.46 | 5.98 | 6.52 |
Average Common Equity |
1.64 | 1.64 | 2.70 | 2.44 | 2.49 | 7.77 | 10.35 | 5.16 | 5.17 | 5.13 |
Columns are period end dates